Japanese Pharmacopoeia
This article was originally published in SRA
Executive Summary
Report considers role of the JP and policy on future editions
You may also be interested in...
UK CBD Limbo Continues – Full List Of ‘Legal’ Products Delayed Until June
A provisional list of CBD products that can continue to legally be sold in the UK has been issued by the Food Standards Agency. However the list currently only includes products from three suppliers and will not be complete until June 2021, meaning the vast majority of companies face a nervy wait.
Biosimilar Education And Innovation Bills Head To Biden’s Desk
The Advancing Education on Biosimilars Act and the Ensuring Innovation Act will be looked at by the US President Joe Biden, after receiving the approval of both the Senate and the House of Representatives. The bills are aimed at lowering prescription drug costs and saving overall healthcare costs.
Alvogen’s Lotus Bags $50m Investment To Boost Access In Asia
Lotus Pharmaceuticals aims to build a stronghold in Thailand and beyond, after the Alvogen subsidiary announced a partnership with a subsidiary of Thai state-owned conglomerate PTT, which includes a $50m capital injection.